Review
Surgery
Aleksandar Bogdanovic, Jelena Djokic Kovac, Predrag Zdujic, Uros Djindjic, Vladimir Dugalic
Summary: This meta-analysis aimed to compare the overall survival after liver resection (LR) versus transarterial chemoembolisation (TACE) for intermediate-stage hepatocellular carcinoma (HCC). The results showed that patients who underwent LR had a significantly longer overall survival than those who underwent TACE.
INTERNATIONAL JOURNAL OF SURGERY
(2023)
Article
Surgery
Victor Lopez-Lopez, Roberto Brusadin, Asuncion Lopez-Conesa, Antonio Capel, Alvaro Navarro-Barrios, Valentin Cayuela, Elena Lopez-Banet, Alejandro Garzon-Arana, Pascual Parrilla-Paricio, Ricardo Robles-Campos
Summary: The study found that in HCC Child A cirrhosis patients, TACE treatment could be beneficial to perform LLR without serious complications and achieve similar oncological outcomes.
LANGENBECKS ARCHIVES OF SURGERY
(2021)
Article
Health Care Sciences & Services
Evgenia Kotsifa, Chrysovalantis Vergadis, Michael Vailas, Nikolaos Machairas, Stylianos Kykalos, Christos Damaskos, Nikolaos Garmpis, Georgios D. Lianos, Dimitrios Schizas
Summary: HCC is the most common primary liver malignancy associated with liver cirrhosis and chronic liver disease. Key risk factors for HCC development include viral infections, alcoholic liver disease, and nonalcoholic fatty liver disease. Treatment options for HCC depend on tumor burden, liver function, and patient's health status, with surgical resection, transplantation, ablation, TACE, and systemic therapy being potential strategies.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Jixue Zou, Jia Yuan, Hong Chen, Xinghao Zhou, Tongchun Xue, Rongxin Chen, Lan Zhang, Zhenggang Ren
Summary: This study developed and validated a nomogram for predicting the prognosis of patients with ruptured hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) treatment. The study identified total bilirubin (TBIL) levels and diameter of the largest tumor as independent prognostic factors for predicting overall survival (OS) in ruptured HCC. The newly developed nomogram can help evaluate the approximate survival rates based on tumor diameter and TBIL level after TACE treatment.
JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Tamas Benkoe, Julia Koenig, Jens M. Theysohn, Clemens Schotten, Fuat H. Saner, Juergen Treckmann, Sonia Radunz
Summary: This study compared the recurrence of HCC after liver transplantation following TACE or radioembolization bridging treatment. The results showed no significant difference in HCC recurrence and overall survival between the radioembolization group and TACE group. Multivariable analysis found recipient age, gender, tumor necrosis, and microvascular invasion to be associated with HCC recurrence.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2022)
Article
Multidisciplinary Sciences
A. Bogdanovic, P. Bulajic, D. Masulovic, N. Bidzic, M. Zivanovic, D. Galun
Summary: The study compared short- and long-term outcomes of patients with huge HCC who underwent potentially curative LR or TACE, finding that LR group had higher overall survival rates both before and after propensity score matching. Total bilirubin and TACE treatment were identified as independent prognostic factors associated with long-term survival.
SCIENTIFIC REPORTS
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim, Korean Liver Cancer Association
Summary: Transarterial chemoembolization (TACE) is a commonly used and important non-surgical treatment for hepatocellular carcinoma (HCC). A group of 12 experts convened by the Korean Liver Cancer Association has developed expert consensus-based practical recommendations in TACE to enhance therapeutic efficacy and safety. These recommendations have been endorsed by the Korean Society of Interventional Radiology and provide useful information and direction in performing TACE procedure as well as pre-and post-procedural patient care.
KOREAN JOURNAL OF RADIOLOGY
(2023)
Article
Multidisciplinary Sciences
William T. N. Culp, Eric G. Johnson, Michelle A. Giuffrida, Robert B. Rebhun, James K. Cawthra, Heidi A. Schwanz, Jenna H. Burton, Michael S. Kent
Summary: This study describes the use of a novel drug-eluting microsphere in transarterial chemoembolization for dogs with non-resectable hepatic neoplasia. The results show significant reduction in tumor volume and improvement in clinical signs.
Article
Oncology
Jiashuo Chao, Qi Zhu, Desheng Chen, Xiao An, Aiqun Liu, Fei Zhou, Lin Yuan, Zhaowen Wang, Hongcheng Sun
Summary: Combination therapy of TACE with tislelizumab may be an effective strategy for converting unresectable hepatocellular carcinoma to resectable, activating immune response and leading to tumor shrinkage, supporting salvage surgery.
FRONTIERS IN ONCOLOGY
(2021)
Article
Surgery
Peng-Sheng Yi, Jun-Ning Liu, Yong Li, Bin Wu, Jian-Shui Li
Summary: This study compared the efficacy of liver resection (LR) and transarterial chemoembolization (TACE) in treating Barcelona Clinic Liver Cancer B1 (BCLC B1) hepatocellular carcinoma. The results showed that the LR group had significantly higher survival rates and progression-free survival rates compared to the TACE group. Tumor distribution and treatment strategy were identified as independent risk factors for overall survival and progression-free survival.
FRONTIERS IN SURGERY
(2022)
Article
Medicine, General & Internal
Sun Young Choi, Kyung Ah Kim, Woosun Choi, Yohan Kwon, Soo Buem Cho
Summary: The study investigated the utility of CBCT-based liver perfusion mapping in assessing treatment response and predicting outcomes in HCC patients undergoing TACE. Results showed that CBCT-based liver perfusion mapping and PBV values were significant in the analysis and demonstrated high sensitivity and specificity in predicting residual tumors. The study highlights the importance of these imaging techniques in enhancing the efficacy of TACE in HCC patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Biao Yang, Minlan Yuan, Ting Yang, Zhengyin Liao, Hao Wu
Summary: This retrospective study evaluates the clinical outcome of transcatheter arterial chemoembolization (TACE) and liver resection (LR) for hepatocellular carcinoma (HCC) in the caudate lobe. The results suggest that TACE may provide a longer overall survival (OS) compared to LR, particularly for patients with CNLC-IIb stage HCC.
Review
Biochemistry & Molecular Biology
Charlotte Ebeling Barbier, Femke Heindryckx, Hans Lennernaes
Summary: Clinical data review highlights the limitations of transarterial chemoembolization (TACE) as a treatment for hepatocellular carcinoma (HCC) and the complex interactions between drug delivery, tumor targeting mechanisms, liver pathophysiology, patient and tumor heterogeneity, and resistance mechanisms. Understanding and addressing these factors are essential to improving the effectiveness of TACE and developing novel drug delivery systems for locoregional treatment of HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Andrei Svecic, Rihab Mansour, An Tang, Samuel Kadoury
Summary: A new Spatial-Temporal Discriminant Graph Neural Network (STDGNN) was proposed to predict future DCE-MRI examinations for HCC treatment response by learning spatio-temporal features from pre-TACE images. The model achieved 93.5% classification accuracy in identifying responses and generated follow-up images with insignificant differences in perfusion parameters compared to ground-truth post-TACE examinations in a dataset of 366 HCCs from liver cancer patients.
Article
Oncology
Wenzhe Fan, Bowen Zhu, Xinlin Zheng, Shufan Yue, Mingjian Lu, Huishuang Fan, Liangliang Qiao, Fuliang Li, Guosheng Yuan, Yanqin Wu, Xinhua Zou, Hongyu Wang, Miao Xue, Jiaping Li
Summary: This study investigated the effectiveness and safety of combining sorafenib and drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of early intrahepatic stage-progressed advanced hepatocellular carcinoma (ISPA-HCC). The results showed that the combination therapy significantly improved tumor response rates, overall survival, and time to progression compared to sorafenib monotherapy. However, the DTS group had a higher incidence of adverse events during treatment.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)